StockNews.com started coverage on shares of Veradigm (NASDAQ:MDRX - Get Free Report) in a note issued to investors on Tuesday. The brokerage set a "hold" rating on the software maker's stock.
Veradigm Price Performance
NASDAQ:MDRX traded up $0.10 on Tuesday, reaching $10.15. The stock had a trading volume of 115,819 shares, compared to its average volume of 1,537,618. Veradigm has a 12-month low of $5.01 and a 12-month high of $12.66. The firm's fifty day moving average is $9.79 and its two-hundred day moving average is $9.57.
Hedge Funds Weigh In On Veradigm
An institutional investor recently bought a new position in Veradigm stock. Innealta Capital LLC bought a new position in Veradigm Inc. (NASDAQ:MDRX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,974 shares of the software maker's stock, valued at approximately $38,000.
Veradigm Company Profile
(
Get Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
See Also
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
